Patent Baristas

Well, I’ve certainly heard from a number of people regarding my earlier post on  the compulsory license granted by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of Bayer’s drug Sorafenib Tosylate (Nexavar), a drug used to treat liver and kidney cancer. The gist of the complaints are that I’m […]

Oh Lord, won’t you buy me a Mercedes Benz? My friends all drive Porsches, I must make amends. Worked hard all my lifetime, no help from my friends, So Lord, won’t you buy me a Mercedes Benz? ~ Janis Joplin Under Section 84 of the Indian Patents Act, 1970, any person can make an application […]

OK, maybe not explode but at least some terrible, Armageddon-like fate.  According to a study by the Federal Trade Commission, pharmaceutical companies are engaging in anti-competitive tactics of paying potential generic rivals to delay the introduction of lower-cost prescription drug alternatives.  The report summarizes data on patent settlements filed with the FTC and the Department […]

“The pharmaceutical industry is trashed nightly as being second only to the tobacco industry in the corporations-we-hate-most department.”    ~ Martin Voet In Martin Voet’s book, The Generic Challenge: Understanding Patents, FDA and Pharmaceutical Life-Cycle Management (third edition), he provides a concise guide to the necessary information so that pharmaceutical executives, managers, regulatory, legal and […]

When: Tuesday, May 03 to Wednesday, May 04, 2011 Where: Marriott Downtown, New York City, NY What: American Conference Institute’s Paragraph IV Disputes conference is the undisputed source for Hatch-Waxman litigation strategies for brand-names and generics. This event — which is widely recognized for setting the standards for Paragraph IV litigation and which also serves […]

When: Tuesday, May 03 to Wednesday, May 04, 2011 Where: Marriott Downtown, New York City, NY What: American Conference Institute’s Paragraph IV Disputes conference is the undisputed source for Hatch-Waxman litigation strategies for brand-names and generics. This event — which is widely recognized for setting the standards for Paragraph IV litigation and which also serves […]

Teva Pharmaceuticals has launched a new online game promotion generic substitution among consumers. The link is below – as you can see, it allows players to replace popular brand-name drugs with their generic equivalents, and it shows how much one would save if they made the switch. According to Teva PR, they’ve had 17,000 views […]

Caraco Pharmaceutical Labs and Sun Pharmaceutical Ind. tried to get a rehearing en banc regarding the counterclaim provision of the Hatch-Waxman Act (HWA).  Novo Nordisk A/S v. Caraco Pharmaceutical Labs and Sun Pharmaceutical Ind., US Court of Appeals for the Federal Circuit (2010-1001). The petition for panel rehearing and for rehearing en banc was denied. […]